Midodrine to optimize heart failure therapy in patients with concurrent hypotension
Related Experiment Video
Updated: Sep 22, 2025

Author Spotlight: Investigating HR-Dependent Cardiac Function in Mouse Models Through a Novel Atrial-Pacing Approach
Published on: July 21, 2023
Paul Shiu1, Gurinder S Grewal2, Teri M Kozik1
1Graduate Medical Education, St. Joseph's Medical Center, Stockton, CA, USA.
Insights
Midodrine can help patients with heart failure and low blood pressure start or continue essential treatments. This alpha-agonist therapy improves clinical outcomes, making guideline-directed medical therapy more tolerable.
Area of Science:
- Cardiology
- Pharmacology
Background:
- Heart failure with reduced ejection fraction (HFrEF) affects millions, with Guideline-Directed Medical Therapy (GDMT) as the standard treatment.
- GDMT includes renin-angiotensin-aldosterone system inhibitors, neprilysin inhibitors, beta-blockers, mineralocorticoid-receptor-antagonists, and SGLT2 inhibitors.
- Refractory hypotension poses a significant barrier to initiating or continuing GDMT in HFrEF patients.
Observation:
- Four cases of HFrEF patients with persistent, baseline hypotension are presented.
- Midodrine, an alpha-adrenergic agonist, was used as a bridge therapy to enable GDMT initiation or continuation.
- Patients experienced marked clinical improvement with outpatient midodrine titration.
Findings:
- Midodrine effectively managed refractory hypotension in HFrEF patients.
- This intervention facilitated the initiation and continuation of GDMT.
- Clinical exacerbations of HFrEF were ameliorated, improving GDMT tolerability.
Implications:
- Midodrine can be a valuable tool for managing HFrEF patients with concomitant hypotension.
- It enables the use of life-saving GDMT in a previously challenging patient population.
- Outpatient midodrine titration may improve long-term outcomes for hypotensive HFrEF patients.
Abstract:
According to the Centers for Disease Control and Prevention statistics, about 6.2 million adults in the United States have heart failure. Guideline-Directed Medical Therapy (GDMT) involving the use of renin-angiotensin-aldosterone system inhibitors with or without a neprilysin inhibitor, β-blockers, mineralocorticoid-receptor-antagonists, and sodium-glucose cotransporter-2 inhibitors serve as the backbone for heart failure with reduced ejection fraction (HFrEF) therapy. However, in patients with refractory hypotension, the initiation of GDMT may not be possible. We present four cases where the use of midodrine, an alpha adrenergic agonist, serves as bridge therapy for the initiation or continuation of GDMT with marked clinical improvement. These cases illustrate how exacerbations of HFrEF may be ameliorated with outpatient midodrine titration among patients with baseline, persistent hypotension such that GDMT may be better tolerated.
More Related Videos
Related Concept Videos
Heart Failure V: Medical Management
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
Heart Failure Drugs: Diuretics
Heart Failure VI: Adjunct Therapies
Heart Failure Drugs: β-Blockers
Heart Failure VII: Nursing Interventions

